Journals / Türkderm-Deri Hastalıkları ve Frengi Arşivi / 2012 / Cilt: 46 - Sayı: 2

Successful use of intravenous immunoglobulin for recalcitrant impetigo herpetiformis: Case report

Tedaviye dirençli impetigo herpetiformis'te intravenöz immunglobulin tedavisinin etkinliği: Olgu sunumu

Pages
104–106
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this case report, we called attention to IVIG therapy in IH, for having the pregnancy continued enough for the fetal maturation before the delivery.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Impetigo herpetiformis (IH), if left untreated, is associated with a high rate of perinatal morbidity and mortality and may lead to the decision of termination of pregnancy.
📊
Key Findings & Data:A 23-year-old woman with a history of plaque psoriasis presented with a sudden generalized pustular eruption on the 25th week of her first gestation.
💡
Conclusion & Impact:In this case report, we called attention to IVIG therapy in IH, for having the pregnancy continued enough for the fetal maturation before the delivery.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Impetigo herpetiformis (IH), if left untreated, is associated with a high rate of perinatal morbidity and mortality and may lead to the decision of termination of pregnancy. There are various and effective therapeutic agents available for the treatment of the disease. A 23-year-old woman with a history of plaque psoriasis presented with a sudden generalized pustular eruption on the 25th week of her first gestation. The diagnosis was made based on the clinical and histopathological findings. The patient was treated with systemic prednisolone (2 mg/kg/d) first and, cyclosporine A (3 mg/kg/d) was added to the treatment after two weeks because prednisolone was not effective alone. The lesions did not regress despite four weeks of combined treatment with prednisolone and cyclosporine. Intravenous immunoglobuline (IVIG) (0.3 g/kg/d, 6 days) was added on the 30th week of gestation and resulted in regression of cutaneous rashes. On the 33rd week of gestation, IVIG (0.7 g/kg/d, 3 days) was repeated due to reactivation of pustules, and an improvement was observed. In this case report, we called attention to IVIG therapy in IH, for having the pregnancy continued enough for the fetal maturation before the delivery.

Özet

İmpetigo herpetiformis (İH), yüksek fetal morbidite ve mortaliteye sahip, bazen gebeliğin sonlandırılmasını gerektirebilen bir hastalıktır. Etkili olduğu belirtilen farklı tedavi seçenekleri bulunmaktadır. Yirmi üç yaşında, psoriazis öyküsü olan 25 haftalık gebe olgu, ani başlangıçlı jeneralize püstüler döküntülerle başvurdu. Klinik bulgular ve histopatolojik değerlendirme ile İH tanısı konuldu. Sistemik prednizolon (2 mg/kg/gün) üç hafta süreyle uygulandı. Yanıt olmadığı için siklosporin A (3mg/kg/gün) ilave edildi. İki hafta siklosporin A ve sistemik prednizolon kombine kullanılmasına rağmen deri bulguları gerilemedi. Tedavilere ek olarak 30. gebelik haftasında intravenöz immunglobulin (IVIG) (0,3 gr/kg/gün, 6 gün) uygulaması ile deri belirtilerinde azalma gözlendi. 33. gebelik haftasında reaktivasyon olduğu için IVIG (0,7g/kg/gün, 3 gün) tekrar verildi. Püstüler lezyonlar geriledi. 34. gebelik haftasında doğum yapan olgunun sağlıklı bir bebeği oldu. Bu olgu sunumu ile İH?de gebeliğin devam etmesi ve fetusun sağlıklı gelişimini sağlaması amacıyla IVIG tedavisine dikkat çekilmektedir.

🔖

Cite This Article

AYDOĞAN, K., BÜLBÜL, E. B., YILDIRIM, S., SARICAOĞLU, H., OZAN, H. (2022). Successful use of intravenous immunoglobulin for recalcitrant impetigo herpetiformis: Case report. Türkderm-Deri Hastalıkları ve Frengi Arşivi, Cilt: 46 - Sayı: 2, 104–106. https://ajindex.com/articles/621925

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Hebra F: Ueber einzine wahrend s wangers chaft, dens wacherbette unde bei uterinal. Krankheiten der Frauen zu beobchtende Hautkrank-heiten. Wien Med Wochenschr 1872;48:1197-202
  2. Breier-Maly J, Ortel B, Breier F, Schmidt JB, Hönigsmann H: Generalized pustular psoriasis of pregnancy (impetigo herpetiformis). Dermatology 1999;198:61-4
  3. Lotem M, Katzenelson V, Rotem A, Hod M, Sandbank M: Impetigo herpetiformis: a variant of pustular psoriasis or a separate entity? J Am Acad Dermatol 1989;20:338-41
  4. Pierard GE, Pierard-Franchimont C, de la Brassinne M: Impetigo herpetiformis and pustular psoriasis during pregnancy. Am J Dermatopathol 1983;5:215-20 5. Imai N, Watanabe R, Fujiwara H, Ito M, Nakamura A: Successful treatment of Impetigo herpetiformis with oral cyclosporine during pregnancy. Arch Dermatol 2002;138:128-29
  5. Jolles S, Hughes J: Use of IVIG in the treatment of atopic dermatitis, urticaria, scleromyxedema, pyoderma gangrenosum, psoriasis and pretibial myxedema. International Immunopharmacology 2006;6:579-91
  6. Hutton B, Sharma R, Fergusson D, et al: Use of ntravenous immunoglobulin for treatment of reccurrent miscarriage: a systemic review. An International Journal of Obstetrics and Gynaecology 2007;114:134-42
  7. Kuijpers ALA, Schalkwijk j, Rulo HFC, et al: Extremely low levels of epidermal skin-derived antileucoproteinase/ elafin in a patient with impetigo herpetiformis. Br J Dermatol 1997;137:123-29
  8. Raychaudhuri SP, Navare T, Gross J, et al: Clinical course of psoriasis during pregnancy. Int J Dermatol 2003;42:518-20
  9. Edmonds EVJ, Morris SD, Short K, Bewley SJ, Eady RAJ: Pustular psoriasis of pregnancy treated with ciclosporin and high dose prednisolone. Clinical and Experimental Dermatology 2005;30:707-26
  10. Lockshin MD, Sammaritano LR: Corticosteroids during pregnancy. Scand J Rheumatol Suppl 1998;107:136-8
  11. Lamarque V, Leleu W, Monka C, Krupp P: Analysis of 629 pregnancy outcomers in renal transplant recipients with Sandimmun. Transplant Proc 1997;29:2480
  12. Giudice PL, Dubourg L, Hadj-Aïssa A, et al: Renal function of children exposed to cyclosporine in utero. Nephrol Dial Transplant 2000;15:1575-79
  13. Bar Oz B, Hackman R, Einarson T, Koren G: Pregnancy outcome after cyclosporine therapy during pregnancy: a met-analysis. Transplantation 2001;71:1051-55
  14. Gurmin V, Mediwake R, Fernando M, et al: Psoriasis: response to high-dose intravenous immunoglobulinin three patients. Br J Dermatol 2002;147;554-57
  15. Taguc